SAVE Act of 2023 Supporting Access to Vital and Affordable Care for Everyone Act of 2023
Impact
If enacted, HB 6161 would specifically affect the tax code by expanding the scope of deductible medical expenses to include purchases of naloxone, a medication that has become increasingly vital for emergency interventions in overdose scenarios. Currently, many individuals may have limited financial ability to obtain naloxone, especially in its over-the-counter form. By enabling individuals to deduct these expenses, the bill aims to reduce the financial burden associated with obtaining necessary medical interventions, potentially increasing the rate at which individuals purchase and carry naloxone.
Summary
House Bill 6161, also known as the 'SAVE Act of 2023,' aims to amend the Internal Revenue Code of 1986 by allowing amounts paid for over-the-counter naloxone to be included in the calculation of medical expense deductions. This legislative move is an effort to enhance the accessibility and affordability of naloxone, a life-saving medication utilized in the treatment of opioid overdoses, thereby addressing the ongoing public health crisis associated with substance abuse. The bill is backed by multiple legislators who recognize the importance of such measures in combating the opioid epidemic by facilitating easier access to treatment options.
Contention
The introduction of HB 6161 may invoke varied responses among stakeholders. Advocates for drug policy reform and public health may support the bill's intentions, as it aligns with broader efforts to enhance healthcare affordability and accessibility. However, opponents may raise concerns about the implications of expanding tax deductions in this manner, questioning whether this approach sufficiently addresses the systemic issues related to substance abuse. Some may argue that more comprehensive measures are needed beyond tax deductions to effectively tackle the opioid crisis.